BofA analyst Tazeen Ahmad upgraded Kymera Therapeutics (KYMR) to Buy from Neutral with a price target of $51, up from $44.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
- Kymera Therapeutics Discusses Phase 1 Study Results
- Kymera Therapeutics Announces Positive Phase 1 Study Results
- Kymera Therapeutics announces first-in-human results for Phase 1 trial of KT-621
- Cautious Hold Rating for Kymera Therapeutics Amid Anticipation of STAT6 Degrader Data
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue